Induction Chemo-Nivo in Unresectable Stage III NSCLC

Lung Cancer, Nonsmall Cell Clinical Trial

Official title:

Phase II Study of Induction Platinum Doublet in Combination With Nivolumab Followed by Surgery or Concurrent Chemoradiation in Unresectable Stage IIIA-C Non-small Cell Lung Cancer (NSCLC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06003075
• Other study ID #: 85869
• Status: Recruiting
• Phase: Phase 2
• Start date: September 22, 2023
• Est. completion date: August 2027

Study information

• Verified date: November 2023
• Source: University of Kentucky
• Contact: Yvonne Taul, RN
• Phone: 859-323-2354
• Email: yvonne.taul[@]uky.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the response rate, safety, and effectiveness of a combination therapy in patients with lung cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 37
• Est. completion date: August 2027
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Squamous and non-squamous non-small cell lung cancer that is at baseline, unresectable stage IIIA-IIIC (8th edition AJCC) and not previously treated
• PD-L1 level needs to be measured with values 0-100% eligible
• EGFR/ALK/ROS1 Wild Type or unknown genetic alterations in these genes
• ECOG Performance Status = 1
• Adequate organ and marrow function
• Adequate pulmonary reserve (e.g., FVC, FEV1, TLC, FRC, and DLCO) capable of tolerating the proposed lung resection
• Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months
• For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
• Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
• Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen
• Clinical risk assessment of cardiac function using the New York Heart Association Functional Classification class 2B or better
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Patients who have participated in a study with an investigational agent or device within 2 weeks of enrollment
• Any prior radiotherapy to the lung
• Any prior treatment for NSCLC
• Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
• Any history of a severe hypersensitivity reaction to any monoclonal antibody
• Any history of allergy to the study drug components
• primary tumors involving the esophagus
• pancoast tumors
• Patients cannot have primary tumors which would remain unresectable
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nivolumab or other agents used in study
• Any active or history of autoimmune disease (including any history of inflammatory bowel disease), or history of syndrome that required systemic steroids or immunosuppressive medications
• Ongoing requirement for systemic corticosteroids greater than the equivalent of prednisone 10mg
• previous malignancies
• history of interstitial lung disease
• Patients requiring continuous supplemental oxygen
• Use of any live vaccines against infectious diseases (e.g., influenza, varicella. etc.) within 4 weeks (28 days) of initiation of study therapy
• Active systemic infection requiring therapy
• Patients with uncontrolled intercurrent illness
• Patients with psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant or lactating women

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Cancer Stage III
• Lung Cancer, Nonsmall Cell
• Lung Neoplasms

Intervention

Combination Product:
• Nivolumab and Chemotherapy
3 cycles of the proposed nivolumab + platinum doublet (either pemetrexed + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for non squamous; or gemcitabine + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for squamous) will be administered then CT and biopsy, followed by surgery with option for post-op NIVO-XRT, then 12 cycles NIVO at 480 mg IV every 4 weeks for 12 weeks

Drug:
• Nivolumab
Participants will receive NIVO at 480 mg IV every 4 weeks for 12 cycles after either surgery or treated with concurrent chemotherapy-nivolumab-radiation

Procedure:
• Post Induction Surgery
Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by surgery in patients whose tumors were unresectable stage IIIA-C at baseline on the basis of lymphadenopathy and are determined to be resectable after responding to induction chemotherapy-nivolumab. The participants have an option for post op XRT, then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles

Radiation:
• Post Induction XRT
Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by concurrent Chemo and Nivo XRT (60Gy). Participants will receive concurrent thoracic radiation therapy using a standardized 3DCRT or IMRT technique on a linear accelerator operating at 2:6 MV beam energy. The target total dose of thoracic radiation therapy will be 60 Gy in 30 daily fractions of 2 Gy prescribed to the PTV. The participants then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles.

Locations

Country	Name	City	State
United States	University of Kentucky	Lexington	Kentucky

Sponsors (2)

Lead Sponsor	Collaborator
Ralph G Zinner	Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate after induction	post induction radiographic response by cat scan	9 weeks
Secondary	Change in Toxicity	To assess safety, investigators will evaluate the rate of toxicity as defined by the Common Toxicity Criteria for Adverse Effects (CTCAE) scoring system.	through study completion, up to 18 months
Secondary	Percent of participants receiving surgery	Rate of converting non-surgical stage III(A-C) to surgically resectable disease	date of surgery, approximately 10 weeks
Secondary	Pathologic complete response (pCR)	Number of participants with Pathologic Complete Response. Pathologic complete response (pCR) is defined by a surgical pathology specimen	post surgery, approximately 10 weeks
Secondary	Major pathological response (MPR)	MPR rate, defined as number of participants with = 10% residual tumor in lung and lymph nodes	post surgery, approximately 10 weeks
Secondary	Progression free survival (PFS)	PFS is defined as the duration of time from start of treatment to time of disease progression or death, whichever occurs first.	2 years
Secondary	overall survival (OS)	defined as the duration of time from start of treatment to time of death	2 years
Secondary	Change in patient-reported Quality of Life as measured by FACT-TOI	patient-reported Quality of Life as measured by FACT-TOI (Functional Assessment of Cancer Therapy - Trial Outcome Index); defined as the sum of the scores of the Physical Well-Being (PWB), Functional Well-Being (FWB), and LCS. PWB, FWB, and LCS (lung cancer scale) scores obtained from 7-item questionnaires from the FACT-L (Version 4.0). Questions are on a 5-point scale from 0-4, where 0 = "not at all" and 4 = "very much." Scores range from 0 to 84; higher score indicates better physical aspects of quality of life (QoL).	through study completion, up to 18 months